EarlyCDT-Lung: extensively validated and excellent academic recognition

  • Over 25 peer-reviewed clinical publications
  • More than 60 peer-reviewed oral and poster presentations at key conferences
  • Technical and clinical performance validated on over 120,000 patient samples and 12 million data points
  • Over 155,000 commercial tests run in our CLIA-certified laboratory in Kansas, USA
  • In a cohort of 296 patients with a pulmonary nodule(s), a positive EarlyCDT-Lung test was associated with a more than 2-fold increase in risk of lung cancer for nodules 4 to <20 mm (n=196)1
  • Combining EarlyCDT-Lung with current malignancy risk assessment methods for pulmonary nodules has shown that a positive EarlyCDT-Lung result can add to the interpretation and re-classify an intermediate risk nodule to expedite intervention2
  • For CT-identified lung nodules, EarlyCDT-Lung’s combined High and Moderate Level test result performance of 93% Specificity, 41% Sensitivity, PPV 59% (1 in 1.7) and 83% Accuracy, make it a valuable ‘rule-in test’ for lung cancer and a key tool to assess nodule malignancy risk3

1Massion PP, Healey GF, Peek LJ, Fredericks L, Sewell HF, Murray A, Robertson JF. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. J Thorac Oncol 2017 Mar;12(3):578-584. doi: 10.1016/j.jtho.2016.08.143. Epub 2016 Sep 8
2 Healey GF, Macdonald IK, Reynolds C, Allen J, Murray A. Tumor-Associated Autoantibodies: Re-Optimization of EarlyCDT-Lung Diagnostic Performance and Its Application to Indeterminate Pulmonary Nodules. J Cancer Therapy 2017; 8:506-517. doi: 10.4236/jct.2017.85043
3 Figures based on lung cancer prevalence 20%


Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept